ixekizumab vs secukinumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriatic Arthritis
Shared mechanism: IL-17 · full Psoriatic Arthritis pipeline
ixekizumab · Taltz
Marketed by Eli Lilly and partners
NCT01695239 · Phase 3 · completed
This randomized, quadruple-blind, placebo- and active-comparator-controlled trial in 417 people with active psoriatic arthritis measured ACR20 response at week 24 as its primary endpoint. Both ixekizumab doses clearly outperformed placebo (57.9% and 62.1% vs 30.2%, p<0.001), and the active comparator adalimumab also beat placebo, confirming the trial could detect a true effect.
Next expected readout: February 2028 · NCT07443956 (registry estimate)
Reported efficacy
Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20) (Week 24): ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001 (met)
Result source: NCT02349295
secukinumab · Cosentyx
Marketed by Novartis
NCT01392326 · Phase 3 · completed
In this large (n=606), randomized, quadruple-blind, placebo-controlled Phase 3 trial in active psoriatic arthritis, significantly more patients achieved an ACR20 response at week 24 on secukinumab 75 mg (50.5%) or 150 mg (50.0%) than on placebo (17.3%), a statistically significant difference for both doses (p<0.0001).
Next expected readout: October 2029 · NCT06751238 (registry estimate)
Reported efficacy
Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28 (Baseline, Week 28): HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002. (met)
Result source: NCT04632927
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ixekizumab | secukinumab |
|---|---|---|
| ACR20 | 53.3% vs 19.5%+33.8 vs placeboNCT023492957 other results
| 51% vs 15.3%+35.7 vs placeboNCT0175263417 other results
|
| ACR50 | 35.2% vs 5.1%+30.1 vs placeboNCT023492954 other results
| 31.4% vs 6.3%+25 vs placeboNCT0420920513 other results
|
| PASI 75 | 57.4% vs 10.4%+47 vs placeboNCT023492951 other result
| 48.3% vs 16.3%+32 vs placeboNCT0175263410 other results
|
| Minimal disease activity | 27.9% vs 3.4%+24.5 vs placeboNCT023492951 other result
| 22.4% vs 5.3%+17.2 vs placeboNCT042092051 other result
|
| HAQ-DI, change | -0.6 vs -0.2−0.4 vs placeboNCT023492955 other results
| -0.5 vs -0.3−0.2 vs placeboNCT0175263412 other results
|
ACR20
- ixekizumab
- 53.3% vs 19.5%+33.8 vs placeboNCT02349295
7 other results
- 48% vs 19.5% NCT02349295
- 57.9% vs 30.2% NCT01695239
- 62.1% vs 30.2% NCT01695239
- 50% vs 22% NCT02349295
- 48% vs 22% NCT02349295
- 57% vs 31.1% NCT01695239
- 60.2% vs 31.1% NCT01695239
- secukinumab
- 51% vs 15.3%+35.7 vs placeboNCT01752634
17 other results
- 42% vs 16.1% NCT01989468
- 59.5% vs 27.4% NCT02404350
- 55.5% vs 27.4% NCT02404350
- 41.2% vs 18.4% NCT02294227
- 39.8% vs 18.4% NCT02294227
- 54% vs 15.3% NCT01752634
- 48.2% vs 16.1% NCT01989468
- 62.6% vs 27.4% NCT02404350
- 29.3% vs 15.3% NCT01752634
- 70% vs 28.6% NCT04711902
- 67.4% vs 61.5% NCT02745080
- 67.5% vs 31.3% NCT02662985
- 56.5% vs 18.5% NCT02721966
- 28.9% vs 19.3% NCT02294227
- 23% vs 19.3% NCT02294227
- 51.6% vs 18.5% NCT02721966
- 59.6% vs 29.0% NCT04209205
ACR50
- ixekizumab
- 35.2% vs 5.1%+30.1 vs placeboNCT02349295
4 other results
- 33.3% vs 5.1% NCT02349295
- 40.2% vs 15.1% NCT01695239
- 46.6% vs 15.1% NCT01695239
- 50.5% vs 46.6% NCT03151551
- secukinumab
- 31.4% vs 6.3%+25 vs placeboNCT04209205
13 other results
- 35% vs 7.1% NCT01752634
- 18.8% vs 8.8% NCT01989468
- 32% vs 8.1% NCT02404350
- 35.9% vs 8.1% NCT02404350
- 22.8% vs 6.1% NCT02294227
- 16.8% vs 6.1% NCT02294227
- 45.8% vs 8.4% NCT02662985
- 35% vs 7.1% NCT01752634
- 34.5% vs 8.8% NCT01989468
- 39.6% vs 8.1% NCT02404350
- 18.2% vs 7.1% NCT01752634
- 15% vs 4.8% NCT04711902
- 49% vs 44.8% NCT02745080
PASI 75
- ixekizumab
- 57.4% vs 10.4%+47 vs placeboNCT02349295
1 other result
- 61.8% vs 10.4% NCT02349295
- secukinumab
- 48.3% vs 16.3%+32 vs placeboNCT01752634
10 other results
- 50% vs 10.2% NCT01989468
- 58.1% vs 12.3% NCT02404350
- 60% vs 12.3% NCT02404350
- 52.7% vs 8.1% NCT02294227
- 50% vs 8.1% NCT02294227
- 63.4% vs 16.3% NCT01752634
- 46.8% vs 10.2% NCT01989468
- 70% vs 12.3% NCT02404350
- 28% vs 16.3% NCT01752634
- 60.7% vs 46% NCT04632927
Minimal disease activity
- ixekizumab
- 27.9% vs 3.4%+24.5 vs placeboNCT02349295
1 other result
- 23.6% vs 3.4% NCT02349295
- secukinumab
- 22.4% vs 5.3%+17.2 vs placeboNCT04209205
1 other result
- 35.7% vs 22.2% NCT04632927
HAQ-DI, change
- ixekizumab
- -0.6 vs -0.2−0.4 vs placeboNCT02349295
5 other results
- -0.4 vs -0.2 NCT02349295
- -0.4 vs -0.2 NCT01695239
- -0.5 vs -0.2 NCT01695239
- -0.8 vs -0.7 NCT02584855
- -0.7 vs -0.6 NCT03151551
- secukinumab
- -0.5 vs -0.3−0.2 vs placeboNCT01752634
12 other results
- -0.3 vs -0.2 NCT01989468
- -0.5 vs -0.2 NCT02404350
- -0.4 vs -0.2 NCT02404350
- -0.3 vs -0.2 NCT02721966
- -0.6 vs -0.3 NCT01752634
- -0.4 vs -0.2 NCT01989468
- -0.6 vs -0.2 NCT02404350
- -0.4 vs -0.2 NCT02721966
- -0.3 vs -0.3 NCT01752634
- -0.4 vs 0.1 NCT04209205
- -0.3 vs 0.1 NCT04711902
- -0.6 vs -0.6 NCT02745080
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety
Coverage. ixekizumab: 16 of 16 rows · secukinumab: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ixekizumab Rows use multiple source trials | secukinumab Rows use multiple source trials |
|---|---|---|
| Dactylitis absolute change · score | -48.3 vs -25.4 placebo score @ 24wkQ2Wa,b,c,d NCT01695239 · Phase 3 show 1 more dose-57.1 vs -25.4 placebo score @ 24wkQ4W NCT01695239 · Phase 3 | 3.08 vs 1.88 placebo score @ 24wk2x 10mg/kgb,c,d NCT00809614 · Phase 2 · registry result, not featured evidence |
| DAS28-CRP absolute change · score | -2.036 vs -0.835 placebo score @ 24wkQ2Wa,c,d NCT01695239 · Phase 3 show 1 more dose-1.955 vs -0.835 placebo score @ 24wkQ4W NCT01695239 · Phase 3 | -1.58 vs -0.96 placebo score @ 24wk150 mg s.c.a,c,d NCT01752634 · Phase 3 show 2 more doses-1.61 vs -0.96 placebo score @ 24wk300 mg s.c. NCT01752634 · Phase 3 -1.12 vs -0.96 placebo score @ 24wk75 mg s.c. NCT01752634 · Phase 3 |
| Enthesitis Resolution responder rate · % of participants | 35.3% (n=68) vs 21.7% (n=69) placebo @ 24wk80 mg Q4Wa,e,d,f NCT02349295 · Phase 3 show 1 more dose31% (n=84) vs 21.7% (n=69) placebo @ 24wk80 mg Q2W NCT02349295 · Phase 3 | 60.5% (n=234) vs 54.2% (n=264) Adalimumab @ 52wk300 mg s.c.e,d,f NCT02745080 · Phase 3 · registry result, not featured evidence |
| Pain VAS absolute change · score | -31.6 vs -14 placebo score @ 24wkQ2Wa,c,d,g NCT01695239 · Phase 3 show 1 more dose-29.6 vs -14 placebo score @ 24wkQ4W NCT01695239 · Phase 3 | -27.1 vs -16.4 Ustekinumab score @ 28wkc,d,g NCT04632927 · Phase 3 |
| PASI 100 responder rate · % of participants | 60.1% (n=283) vs 46.6% (n=283) Adalimumab @ 24wkh,e,d,g NCT03151551 · Phase 4 · registry result, not featured evidence | 37.5% (n=56) vs 27% (n=63) Ustekinumab @ 28wk*h,e,d,g NCT04632927 · Phase 3 · converted to % from 21 Participants as posted |
| Patient Global Assessment absolute change · mm | -40.61 vs -37.82 Adalimumab mm @ 52wkh,e,d,i NCT03151551 · Phase 4 · registry result, not featured evidence | -25.87 vs -16.61 placebo mm @ 24wkh,e,d,i NCT02771210 · Phase 3 · registry result, not featured evidence |
| Physician Global Assessment absolute change · mm | -48.15 vs -46.79 Adalimumab mm @ 52wkh,e,d,i NCT03151551 · Phase 4 · registry result, not featured evidence | -34.88 vs -18.93 placebo mm @ 24wkh,e,d,i NCT02771210 · Phase 3 · registry result, not featured evidence |
| PsARC responder rate · % of participants | 66% (n=103) vs 32.1% (n=106) placebo @ 24wkQ2Wa,b,c,d NCT01695239 · Phase 3 show 1 more dose57.9% (n=107) vs 32.1% (n=106) placebo @ 24wkQ4W NCT01695239 · Phase 3 | 50% (n=24) vs 36% (n=13) placebo @ 24wk2x 10mg/kgb,c,d NCT00809614 · Phase 2 · registry result, not featured evidence |
| SF-36 PCS absolute change · score | 10.07 vs 9.55 Adalimumab score @ 52wkh,e,d,j NCT03151551 · Phase 4 · registry result, not featured evidence | 4.28 vs 0.08 placebo score @ 16wk150 mgh,e,d,j NCT04711902 · Phase 3 · registry result, not featured evidence 3 other source trials6.47 vs 2.34 placebo score @ 16wk6 mg/kg - 3 mg/kg i.v. NCT04209205 · Phase 3 · registry result, not featured evidence 3.42 vs 0.63 placebo score @ 16wk150 mg NCT02294227 · Phase 3 · registry result, not featured evidence 3.44 vs 0.63 placebo score @ 16wk150 mg NCT02294227 · Phase 3 · registry result, not featured evidence |
| SPARCC Enthesitis Index absolute change · score | -3.93 vs -4.06 Adalimumab score @ 52wkh,e,d,k NCT03151551 · Phase 4 · registry result, not featured evidence | -2.23 vs -1.57 placebo score @ 12wk150 mg + 300 mgh,e,d,k NCT02662985 · Phase 3 · registry result, not featured evidence 2 other source trials-2.2 vs -1.7 placebo score @ 12wk150 mg NCT02721966 · Phase 3 · registry result, not featured evidence -2.4 vs -1.7 placebo score @ 12wk300 mg NCT02721966 · Phase 3 · registry result, not featured evidence |
| Swollen Joint Count absolute change · score | -9.58 vs -9.53 Adalimumab score @ 52wkh,e,d,l NCT03151551 · Phase 4 · registry result, not featured evidence | -6.8 vs -5.3 Ustekinumab score @ 28wkh,e,d,l NCT04632927 · Phase 3 |
| TJC absolute change · score | -15.91 vs -14.88 Adalimumab score @ 52wkh,e,d,l NCT03151551 · Phase 4 · registry result, not featured evidence | -9.6 vs -7.6 Ustekinumab score @ 28wkh,e,d,l NCT04632927 · Phase 3 |
| Dropout rate | —Q2Wm NCT01695239 · Phase 3 show 22 more results—Q4W NCT01695239 · Phase 3 6.8%Q2W NCT01695239 · Phase 3 9.3%Q4W NCT01695239 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 —80 mg Q4W NCT02349295 · Phase 3 —80 mg Q4W NCT02349295 · Phase 3 9%80 mg Q4W NCT02349295 · Phase 3 —80 mg Q2W NCT02349295 · Phase 3 —80 mg Q2W NCT02349295 · Phase 3 11.4%80 mg Q2W NCT02349295 · Phase 3 6%Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence 6%Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence —Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 6.4%Ixekizumab NCT03151551 · Phase 4 · registry result, not featured evidence —Ixekizumab Follow-up NCT03151551 · Phase 4 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —Ixekizumab NCT02584855 · Phase 3 · registry result, not featured evidence 26.1%Ixekizumab Open Label NCT02584855 · Phase 3 · registry result, not featured evidence | —150 mgm NCT01392326 · Phase 3 show 46 more results—75 mg NCT01392326 · Phase 3 5%150 mg s.c. NCT01752634 · Phase 3 3%300 mg s.c. NCT01752634 · Phase 3 6.1%75 mg s.c. NCT01752634 · Phase 3 0%Secukinumab NCT04632927 · Phase 3 —Secukinumab - Entire Study NCT04632927 · Phase 3 —Secukinumab- On-Treatment NCT04632927 · Phase 3 — NCT03031782 · Phase 3 2.7%150 mg with load NCT02404350 · Phase 3 6.8%150 mg without load NCT02404350 · Phase 3 2.7%300 mg with load NCT02404350 · Phase 3 —150 mg NCT02798211 · Phase 4 · registry result, not featured evidence —300 mg NCT02798211 · Phase 4 · registry result, not featured evidence —150 mg NCT03769168 · Phase 3 · registry result, not featured evidence 66.7%150 mg NCT03769168 · Phase 3 · registry result, not featured evidence —300 mg NCT03769168 · Phase 3 · registry result, not featured evidence —75 mg NCT03769168 · Phase 3 · registry result, not featured evidence 47.4%75 mg NCT03769168 · Phase 3 · registry result, not featured evidence —150 mg NCT04711902 · Phase 3 · registry result, not featured evidence 0%150 mg NCT04711902 · Phase 3 · registry result, not featured evidence —300 mg NCT04711902 · Phase 3 · registry result, not featured evidence —6 mg/kg - 3 mg/kg i.v NCT04209205 · Phase 3 · registry result, not featured evidence 9.4%6 mg/kg - 3 mg/kg i.v. NCT04209205 · Phase 3 · registry result, not featured evidence 1.2%150 mg + 300 mg NCT02662985 · Phase 3 · registry result, not featured evidence —150+300 mg NCT02662985 · Phase 3 · registry result, not featured evidence —300 mg NCT02745080 · Phase 3 · registry result, not featured evidence 12.9%300 mg s.c. NCT02745080 · Phase 3 · registry result, not featured evidence 10.8% NCT02771210 · Phase 3 · registry result, not featured evidence 13.9%150 mg NCT02721966 · Phase 3 · registry result, not featured evidence —150 mg NCT02721966 · Phase 3 · registry result, not featured evidence 17.4%300 mg NCT02721966 · Phase 3 · registry result, not featured evidence —300 mg NCT02721966 · Phase 3 · registry result, not featured evidence 34.1%150 mg NCT01989468 · Phase 3 · registry result, not featured evidence 26.6%300 mg NCT01989468 · Phase 3 · registry result, not featured evidence —150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 18.7%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 18%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence —300 mg NCT01892436 · Phase 3 · registry result, not featured evidence —75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 14.9%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 15.6%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 21.9%150 mg NCT02294227 · Phase 3 · registry result, not featured evidence 22.1%150 mg NCT02294227 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT01169844 · Phase 2 · registry result, not featured evidence 10.7%2x 10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence —2x10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —Q2Wm NCT01695239 · Phase 3 show 22 more results—Q4W NCT01695239 · Phase 3 2.9%Q2W NCT01695239 · Phase 3 1.9%Q4W NCT01695239 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 —80 mg Q4W NCT02349295 · Phase 3 —80 mg Q4W NCT02349295 · Phase 3 4.1%80 mg Q4W NCT02349295 · Phase 3 —80 mg Q2W NCT02349295 · Phase 3 —80 mg Q2W NCT02349295 · Phase 3 5.7%80 mg Q2W NCT02349295 · Phase 3 —Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence —Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 0%Ixekizumab NCT03151551 · Phase 4 · registry result, not featured evidence —Ixekizumab Follow-up NCT03151551 · Phase 4 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —Ixekizumab NCT02584855 · Phase 3 · registry result, not featured evidence 3.6%Ixekizumab Open Label NCT02584855 · Phase 3 · registry result, not featured evidence | —150 mgm NCT01392326 · Phase 3 show 46 more results—75 mg NCT01392326 · Phase 3 0%150 mg s.c. NCT01752634 · Phase 3 2%300 mg s.c. NCT01752634 · Phase 3 3%75 mg s.c. NCT01752634 · Phase 3 0%Secukinumab NCT04632927 · Phase 3 —Secukinumab - Entire Study NCT04632927 · Phase 3 —Secukinumab- On-Treatment NCT04632927 · Phase 3 — NCT03031782 · Phase 3 0.9%150 mg with load NCT02404350 · Phase 3 0.9%150 mg without load NCT02404350 · Phase 3 1.4%300 mg with load NCT02404350 · Phase 3 —150 mg NCT02798211 · Phase 4 · registry result, not featured evidence —300 mg NCT02798211 · Phase 4 · registry result, not featured evidence —150 mg NCT03769168 · Phase 3 · registry result, not featured evidence 2.8%150 mg NCT03769168 · Phase 3 · registry result, not featured evidence —300 mg NCT03769168 · Phase 3 · registry result, not featured evidence —75 mg NCT03769168 · Phase 3 · registry result, not featured evidence 0%75 mg NCT03769168 · Phase 3 · registry result, not featured evidence —150 mg NCT04711902 · Phase 3 · registry result, not featured evidence —150 mg NCT04711902 · Phase 3 · registry result, not featured evidence —300 mg NCT04711902 · Phase 3 · registry result, not featured evidence —6 mg/kg - 3 mg/kg i.v NCT04209205 · Phase 3 · registry result, not featured evidence 1%6 mg/kg - 3 mg/kg i.v. NCT04209205 · Phase 3 · registry result, not featured evidence 0%150 mg + 300 mg NCT02662985 · Phase 3 · registry result, not featured evidence —150+300 mg NCT02662985 · Phase 3 · registry result, not featured evidence —300 mg NCT02745080 · Phase 3 · registry result, not featured evidence 3.1%300 mg s.c. NCT02745080 · Phase 3 · registry result, not featured evidence 4.9% NCT02771210 · Phase 3 · registry result, not featured evidence 2.4%150 mg NCT02721966 · Phase 3 · registry result, not featured evidence —150 mg NCT02721966 · Phase 3 · registry result, not featured evidence 2.4%300 mg NCT02721966 · Phase 3 · registry result, not featured evidence —300 mg NCT02721966 · Phase 3 · registry result, not featured evidence 7.2%150 mg NCT01989468 · Phase 3 · registry result, not featured evidence 10.8%300 mg NCT01989468 · Phase 3 · registry result, not featured evidence —150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 4%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 3.7%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence —300 mg NCT01892436 · Phase 3 · registry result, not featured evidence —75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 2.7%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 4.8%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 5.3%150 mg NCT02294227 · Phase 3 · registry result, not featured evidence 7.1%150 mg NCT02294227 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT01169844 · Phase 2 · registry result, not featured evidence —2x 10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence —2x10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%Q2Wm NCT01695239 · Phase 3 show 22 more results0%Q4W NCT01695239 · Phase 3 10.4%Q2W NCT01695239 · Phase 3 15%Q4W NCT01695239 · Phase 3 5.6%Q2W NCT01695239 · Phase 3 2.9%Q4W NCT01695239 · Phase 3 0%80 mg Q4W NCT02349295 · Phase 3 11.7%80 mg Q4W NCT02349295 · Phase 3 2.5%80 mg Q4W NCT02349295 · Phase 3 0%80 mg Q2W NCT02349295 · Phase 3 9.3%80 mg Q2W NCT02349295 · Phase 3 6.5%80 mg Q2W NCT02349295 · Phase 3 —Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence 0.5%Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 0%Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 4.2%Ixekizumab NCT03151551 · Phase 4 · registry result, not featured evidence 2.6%Ixekizumab Follow-up NCT03151551 · Phase 4 · registry result, not featured evidence 4.5%80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence 1.1%80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence 1%80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence 1.3%Ixekizumab NCT02584855 · Phase 3 · registry result, not featured evidence 5.1%Ixekizumab Open Label NCT02584855 · Phase 3 · registry result, not featured evidence | 17.3%150 mgm NCT01392326 · Phase 3 show 46 more results11%75 mg NCT01392326 · Phase 3 —150 mg s.c. NCT01752634 · Phase 3 —300 mg s.c. NCT01752634 · Phase 3 —75 mg s.c. NCT01752634 · Phase 3 —Secukinumab NCT04632927 · Phase 3 7.1%Secukinumab - Entire Study NCT04632927 · Phase 3 5.4%Secukinumab- On-Treatment NCT04632927 · Phase 3 14.6% NCT03031782 · Phase 3 4.1%150 mg with load NCT02404350 · Phase 3 2.7%150 mg without load NCT02404350 · Phase 3 3.2%300 mg with load NCT02404350 · Phase 3 3.9%150 mg NCT02798211 · Phase 4 · registry result, not featured evidence 7.9%300 mg NCT02798211 · Phase 4 · registry result, not featured evidence 9.3%150 mg NCT03769168 · Phase 3 · registry result, not featured evidence —150 mg NCT03769168 · Phase 3 · registry result, not featured evidence 0%300 mg NCT03769168 · Phase 3 · registry result, not featured evidence 0%75 mg NCT03769168 · Phase 3 · registry result, not featured evidence —75 mg NCT03769168 · Phase 3 · registry result, not featured evidence 0%150 mg NCT04711902 · Phase 3 · registry result, not featured evidence —150 mg NCT04711902 · Phase 3 · registry result, not featured evidence 4.8%300 mg NCT04711902 · Phase 3 · registry result, not featured evidence 5.9%6 mg/kg - 3 mg/kg i.v NCT04209205 · Phase 3 · registry result, not featured evidence —6 mg/kg - 3 mg/kg i.v. NCT04209205 · Phase 3 · registry result, not featured evidence —150 mg + 300 mg NCT02662985 · Phase 3 · registry result, not featured evidence 5.6%150+300 mg NCT02662985 · Phase 3 · registry result, not featured evidence 8.7%300 mg NCT02745080 · Phase 3 · registry result, not featured evidence —300 mg s.c. NCT02745080 · Phase 3 · registry result, not featured evidence 6.9% NCT02771210 · Phase 3 · registry result, not featured evidence —150 mg NCT02721966 · Phase 3 · registry result, not featured evidence 5.7%150 mg NCT02721966 · Phase 3 · registry result, not featured evidence —300 mg NCT02721966 · Phase 3 · registry result, not featured evidence 5.6%300 mg NCT02721966 · Phase 3 · registry result, not featured evidence —150 mg NCT01989468 · Phase 3 · registry result, not featured evidence —300 mg NCT01989468 · Phase 3 · registry result, not featured evidence 20.3%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence —150 mg NCT01892436 · Phase 3 · registry result, not featured evidence —150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 6.1%300 mg NCT01892436 · Phase 3 · registry result, not featured evidence 16.4%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence —75 mg NCT01892436 · Phase 3 · registry result, not featured evidence —75 mg NCT01892436 · Phase 3 · registry result, not featured evidence —150 mg NCT02294227 · Phase 3 · registry result, not featured evidence —150 mg NCT02294227 · Phase 3 · registry result, not featured evidence 26.3%3 mg/kg NCT01169844 · Phase 2 · registry result, not featured evidence —2x 10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence 14.3%2x10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | Q2Wm back pain 0% (placebo 0%) bronchitis 0% (placebo 2.8%) injection site erythema 0% (placebo 0%) NCT01695239 · Phase 3 show 20 more resultsQ4W back pain 0% (placebo 0%) bronchitis 0% (placebo 2.8%) injection site erythema 0% (placebo 0%) NCT01695239 · Phase 3 Q2W viral upper respiratory tract infection 11.5% (placebo 4.7%) upper respiratory tract infection 9.8% (placebo 6.6%) injection site reaction 7.1% (placebo 0%) NCT01695239 · Phase 3 Q4W upper respiratory tract infection 11.2% (placebo 6.6%) viral upper respiratory tract infection 11.2% (placebo 4.7%) injection site reaction 6.4% (placebo 0%) NCT01695239 · Phase 3 Q2W injection site reaction 12.1% (placebo 0%) injection site erythema 6.5% (placebo 0%) viral upper respiratory tract infection 5.6% (placebo 4.7%) NCT01695239 · Phase 3 Q4W injection site reaction 15.7% (placebo 0%) injection site erythema 12.7% (placebo 0%) bronchitis 2.9% (placebo 2.8%) NCT01695239 · Phase 3 80 mg Q4W ear infection 6.7% (placebo 0.8%) goitre 6.7% (placebo 0%) hepatic steatosis 6.7% (placebo 0.8%) NCT02349295 · Phase 3 80 mg Q4W nasopharyngitis 18% (placebo 3.4%) upper respiratory tract infection 13.5% (placebo 7.6%) bronchitis 9.9% (placebo 3.4%) NCT02349295 · Phase 3 80 mg Q4W upper respiratory tract infection 9.8% (placebo 7.6%) nasopharyngitis 7.4% (placebo 3.4%) oropharyngeal pain 5.7% (placebo 0%) NCT02349295 · Phase 3 80 mg Q2W injection site pain 11.8% (placebo 1.7%) injection site reaction 11.8% (placebo 0.8%) vulvovaginal candidiasis 8.3% (placebo 0%) NCT02349295 · Phase 3 80 mg Q2W upper respiratory tract infection 18.7% (placebo 7.6%) nasopharyngitis 14% (placebo 3.4%) bronchitis 10.3% (placebo 3.4%) NCT02349295 · Phase 3 80 mg Q2W injection site reaction 12.2% (placebo 0.8%) upper respiratory tract infection 9.8% (placebo 7.6%) hypertension 4.9% (placebo 2.5%) NCT02349295 · Phase 3 Q2W/Q4W latent tuberculosis 8.6% pyrexia 8.6% injection site erythema 1.9% NCT05855967 · Phase 4 · registry result, not featured evidence Q4W latent tuberculosis 9.8% urinary tract infection 4.9% c-reactive protein increased 2.4% NCT05855967 · Phase 4 · registry result, not featured evidence nasopharyngitis 13.4% upper respiratory tract infection 6.4% injection site reaction 5.7% NCT03151551 · Phase 4 · registry result, not featured evidence nasopharyngitis 1.9% upper respiratory tract infection 1.1% injection site reaction 0% NCT03151551 · Phase 4 · registry result, not featured evidence 80 mg every 2 weeks nasopharyngitis 14.3% (placebo 5.1%) upper respiratory tract infection 9% (placebo 5.1%) bronchitis 3.8% (placebo 1.3%) NCT02584855 · Phase 3 · registry result, not featured evidence 80 mg every 2 weeks upper respiratory tract infection 2.3% (placebo 5.1%) psoriasis 1.1% (placebo 5.1%) alanine aminotransferase increased 0.8% (placebo 1.3%) NCT02584855 · Phase 3 · registry result, not featured evidence 80 mg every 2 weeks nasopharyngitis 13.4% (placebo 5.1%) upper respiratory tract infection 9.3% (placebo 5.1%) injection site reaction 7.2% (placebo 0%) NCT02584855 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.9% (placebo 5.1%) upper respiratory tract infection 11.4% (placebo 5.1%) uterine leiomyoma 6.3% (placebo 0%) NCT02584855 · Phase 3 · registry result, not featured evidence injection site reaction 15% (placebo 0%) upper respiratory tract infection 12.4% (placebo 5.1%) nasopharyngitis 8.6% (placebo 5.1%) NCT02584855 · Phase 3 · registry result, not featured evidence | 150 mgm upper respiratory tract infection 20.3% (placebo 5.9%) nasopharyngitis 18.3% (placebo 5.4%) headache 8.5% (placebo 3.5%) NCT01392326 · Phase 3 show 25 more results75 mg nasopharyngitis 20.9% (placebo 5.4%) upper respiratory tract infection 17.8% (placebo 5.9%) back pain 9.9% (placebo 1%) NCT01392326 · Phase 3 nasopharyngitis 33.3% (placebo 28.9%) diarrhoea 22.9% (placebo 15.8%) nausea 22.9% (placebo 21.1%) NCT03031782 · Phase 3 150 mg with load upper respiratory tract infection 7.7% (placebo 3.3%) viral upper respiratory tract infection 6.8% (placebo 8.7%) pruritus 5% (placebo 1.2%) NCT02404350 · Phase 3 150 mg without load upper respiratory tract infection 6.3% (placebo 3.3%) viral upper respiratory tract infection 5.9% (placebo 8.7%) hypertension 4.1% (placebo 3%) NCT02404350 · Phase 3 300 mg with load viral upper respiratory tract infection 6.3% (placebo 8.7%) diarrhoea 4.1% (placebo 6.6%) bronchitis 3.6% (placebo 0.6%) NCT02404350 · Phase 3 150 mg back pain 7.8% (placebo 15.4%) diarrhoea 6.8% (placebo 3.8%) hypertension 5.8% (placebo 0%) NCT02798211 · Phase 4 · registry result, not featured evidence 300 mg upper respiratory tract infection 13.6% (placebo 1.9%) diarrhoea 5.8% (placebo 3.8%) back pain 5.2% (placebo 15.4%) NCT02798211 · Phase 4 · registry result, not featured evidence 150 mg covid-19 20.9% nasopharyngitis 18.6% pain in extremity 18.6% NCT03769168 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 25% arthralgia 18.8% covid-19 18.8% NCT03769168 · Phase 3 · registry result, not featured evidence 75 mg arthralgia 21.1% abdominal pain upper 15.8% back pain 10.5% NCT03769168 · Phase 3 · registry result, not featured evidence 150 mg hyperlipidaemia 20% (placebo 38.1%) hypercholesterolaemia 16.7% (placebo 0%) hyperuricaemia 16.7% (placebo 9.5%) NCT04711902 · Phase 3 · registry result, not featured evidence 300 mg covid-19 23.8% (placebo 0%) hyperuricaemia 19% (placebo 9.5%) hyperlipidaemia 14.3% (placebo 38.1%) NCT04711902 · Phase 3 · registry result, not featured evidence 6 mg/kg - 3 mg/kg i.v covid-19 9.9% (placebo 3.7%) urinary tract infection 4.5% (placebo 0.5%) arthralgia 3.7% (placebo 1.6%) NCT04209205 · Phase 3 · registry result, not featured evidence 150+300 mg nasopharyngitis 11.8% (placebo 4.8%) headache 8.1% (placebo 3.6%) urinary tract infection 6.2% (placebo 3.6%) NCT02662985 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 20.7% upper respiratory tract infection 9.9% headache 8.5% NCT02745080 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.7% diarrhoea 7.8% arthralgia 6.9% NCT02771210 · Phase 3 · registry result, not featured evidence 150 mg nasopharyngitis 9% (placebo 6.6%) upper respiratory tract infection 5.7% (placebo 3%) pharyngitis 5.3% (placebo 3%) NCT02721966 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 13.7% (placebo 6.6%) diarrhoea 6.5% (placebo 2.4%) upper respiratory tract infection 4.8% (placebo 3%) NCT02721966 · Phase 3 · registry result, not featured evidence 150 mg nasopharyngitis 21.4% (placebo 5.4%) upper respiratory tract infection 19.2% (placebo 5.9%) headache 8.9% (placebo 3.5%) NCT01892436 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 8.5% (placebo 5.4%) upper respiratory tract infection 6.1% (placebo 5.9%) bronchitis 5.5% (placebo 3%) NCT01892436 · Phase 3 · registry result, not featured evidence 75 mg nasopharyngitis 24% (placebo 5.4%) upper respiratory tract infection 21.2% (placebo 5.9%) headache 10.6% (placebo 3.5%) NCT01892436 · Phase 3 · registry result, not featured evidence 3 mg/kg nasopharyngitis 36.8% (placebo 44.4%) arthralgia 26.3% (placebo 22.2%) oropharyngeal pain 26.3% (placebo 33.3%) NCT01169844 · Phase 2 · registry result, not featured evidence 2x10mg/kg nasopharyngitis 25% (placebo 35.7%) headache 21.4% (placebo 7.1%) dizziness 14.3% (placebo 0%) NCT00809614 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation context differs: registered conditions differ.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for both studies.
- fAssessment timepoints differ: 52 weeks versus 24 weeks.
- gAssessment timepoints differ: 28 weeks versus 24 weeks.
- hTrial phases differ: Phase 3 versus Phase 4.
- iAssessment timepoints differ: 24 weeks versus 52 weeks.
- jAssessment timepoints differ: 16 weeks versus 52 weeks.
- kAssessment timepoints differ: 12 weeks versus 52 weeks.
- lAssessment timepoints differ: 28 weeks versus 52 weeks.
- mPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ixekizumab
show 3 more results
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 6 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 28 further endpoints in the CSV export.
secukinumab
show 10 more results
show 2 more results
show 1 more result
+ 81 further endpoints in the CSV export.
Psoriasis
Shared mechanism: IL-17 · full Psoriasis pipeline
ixekizumab · Taltz
Marketed by Eli Lilly and partners
NCT01474512 · Phase 3 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 1,296 participants. Its clinical primary endpoints, sPGA 0/1 and PASI75 at Week 12, were met for both ixekizumab regimens versus placebo, with p<0.001 for each comparison.
Next expected readout: December 2027 · NCT04537689 (registry estimate)
Reported efficacy
Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20]): ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. (met)
Result source: NCT01695239
secukinumab · Cosentyx
Marketed by Novartis
NCT01358578 · Phase 3 · completed
This was a large, randomized, quadruple-blind trial with both placebo and active etanercept comparator groups, enrolling 1,306 participants. The clinical primary endpoints at week 12 were met in the favorable direction based on the reported counts: PASI 75 and IGA 0/1 responses were achieved by large majorities of secukinumab-treated participants compared with very few placebo-treated participants, although formal statistical analyses are not posted in the registry.
Next expected readout: December 2027 · NCT04239859 (registry estimate)
Reported efficacy
Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks); Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12 (12 wks): Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%) (met)
Result source: NCT01358578
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ixekizumab | secukinumab |
|---|---|---|
| PASI 75 | 84.2% vs 7.3%+76.9 vs placeboNCT0164617716 other results
| 77.1% vs 4.9%+72.2 vs placeboNCT0135857827 other results
|
| PASI 90 | 72.8% vs 42.2%vs UstekinumabNCT025618069 other results
| 66.5% vs 48%vs UstekinumabNCT0282660323 other results
|
| PASI 100 | 35% vs 0%+35 vs placeboNCT0164617710 other results
| 23.5% vs 0%+23.5 vs placeboNCT0226713513 other results
|
| sPGA 0/1 | 75.4% vs 6.7%+68.7 vs placeboNCT0164617716 other results
| 62.5% vs 2.8%+59.7 vs placeboNCT013585783 other results
|
| DLQI, change | -9.6 vs -1.7−7.9 vs placeboNCT0164617712 other results
| -13.2 vs -2.0−11.2 vs placeboNCT035898851 other result
|
PASI 75
- ixekizumab
- 84.2% vs 7.3%+76.9 vs placeboNCT01646177
16 other results
- 87.3% vs 7.3% NCT01646177
- 87.4% vs 8% NCT03364309
- 93.8% vs 8% NCT03364309
- 82.6% vs 3.9% NCT01474512
- 89.1% vs 3.9% NCT01474512
- 77.5% vs 2.4% NCT01597245
- 89.7% vs 2.4% NCT01597245
- 88.7% vs 25% NCT03073200
- 53.9% vs 8.9% NCT03073200
- 84.2% vs 26.3% NCT03073200
- 88.2% vs 68.7% NCT02561806
- 82.1% vs 7.7% NCT01107457
- 82.8% vs 7.7% NCT01107457
- 76.7% vs 7.7% NCT01107457
- 28.6% vs 7.7% NCT01107457
- 22.9% vs 5.1% NCT03573323
- secukinumab
- 77.1% vs 4.9%+72.2 vs placeboNCT01358578
27 other results
- 81.6% vs 4.5% NCT01365455
- 93.4% vs 4.4% NCT03066609
- 67% vs 4.9% NCT01358578
- 71.6% vs 4.5% NCT01365455
- 75.9% vs 0% NCT01555125
- 82.4% vs 4.4% NCT03066609
- 95.1% vs 10% NCT03589885
- 69.5% vs 0% NCT01555125
- 88.9% vs 1.4% NCT02748863
- 80% vs 14.6% NCT02471144
- 77.5% vs 14.6% NCT02471144
- 64.7% vs 2% NCT02267135
- 77.1% vs 44% NCT01358578
- 88% vs 74.1% NCT02826603
- 92% vs 79.9% NCT02826603
- 40.2% vs 16.3% NCT02826603
- 49.7% vs 20.6% NCT02074982
- 67% vs 44% NCT01358578
- 87.6% vs 21.1% NCT02474082
- 80% vs 8.4% NCT02474082
- 88.6% vs 27.4% NCT02474082
- 69.5% vs 2.1% NCT02474082
- 47.6% vs 1.1% NCT02474082
- 24.8% vs 0% NCT02474082
- 5.7% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 84.8% vs 0% NCT02690701
PASI 90
- ixekizumab
- 72.8% vs 42.2%vs UstekinumabNCT02561806
9 other results
- 65.3% vs 3.1% NCT01646177
- 68.1% vs 3.1% NCT01646177
- 75.9% vs 2.3% NCT03364309
- 82.4% vs 2.3% NCT03364309
- 59.7% vs 0.6% NCT01597245
- 70.7% vs 0.6% NCT01597245
- 78.3% vs 5.4% NCT03073200
- 58.5% vs 35.9% NCT03573323
- 21% vs 7.9% NCT03573323
- secukinumab
- 66.5% vs 48%vs UstekinumabNCT02826603
23 other results
- 79% vs 57.3% NCT02074982
- 54.2% vs 1.5% NCT01358578
- 59.2% vs 1.2% NCT01365455
- 77.2% vs 1.5% NCT03066609
- 41.9% vs 1.5% NCT01358578
- 39.1% vs 1.2% NCT01365455
- 62.5% vs 1.5% NCT03066609
- 75.6% vs 5% NCT03589885
- 47.1% vs 0% NCT02267135
- 66.7% vs 1.4% NCT02748863
- 72.5% vs 2.4% NCT02471144
- 67.5% vs 2.4% NCT02471144
- 76.9% vs 54.2% NCT02826603
- 63.8% vs 2.1% NCT02474082
- 46.7% vs 1.1% NCT02474082
- 68.6% vs 8.4% NCT02474082
- 32.4% vs 0% NCT02474082
- 17.1% vs 0% NCT02474082
- 2.9% vs 0% NCT02474082
- 1.9% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 53.7% vs 0% NCT03055494
- 73.9% vs 0% NCT02690701
PASI 100
- ixekizumab
- 35% vs 0%+35 vs placeboNCT01646177
10 other results
- 37.7% vs 0% NCT01646177
- 29.3% vs 0% NCT03364309
- 33% vs 0% NCT03364309
- 30.8% vs 0.6% NCT01597245
- 40.5% vs 0.6% NCT01597245
- 49.6% vs 1.8% NCT03073200
- 36% vs 14.5% NCT02561806
- 41.3% vs 24.9% NCT03573323
- 29.6% vs 13.6% NCT03573323
- 6.7% vs 1.4% NCT03573323
- secukinumab
- 23.5% vs 0%+23.5 vs placeboNCT02267135
13 other results
- 38.9% vs 0% NCT02748863
- 36.6% vs 0% NCT02748863
- 38.2% vs 20.1% NCT02826603
- 45.5% vs 26.6% NCT02826603
- 28.6% vs 0% NCT02474082
- 15.2% vs 0% NCT02474082
- 37.1% vs 0% NCT02474082
- 7.6% vs 0% NCT02474082
- 3.8% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 37% vs 0% NCT02690701
sPGA 0/1
- ixekizumab
- 75.4% vs 6.7%+68.7 vs placeboNCT01646177
16 other results
- 80.5% vs 6.7% NCT01646177
- 79.9% vs 3.4% NCT03364309
- 86.4% vs 3.4% NCT03364309
- 76.4% vs 3.2% NCT01474512
- 81.8% vs 3.2% NCT01474512
- 72.9% vs 2.4% NCT01597245
- 83.2% vs 2.4% NCT01597245
- 80.9% vs 10.7% NCT03073200
- 73.3% vs 2.7% NCT02718898
- 47.8% vs 7.1% NCT03073200
- 76.3% vs 5.3% NCT03073200
- 83.6% vs 57.2% NCT02561806
- 71.4% vs 7.7% NCT01107457
- 72.4% vs 7.7% NCT01107457
- 70% vs 7.7% NCT01107457
- 25% vs 7.7% NCT01107457
- secukinumab
- 62.5% vs 2.8%+59.7 vs placeboNCT01358578
3 other results
- 51.1% vs 2.8% NCT01358578
- 62.5% vs 27.2% NCT01358578
- 51.1% vs 27.2% NCT01358578
DLQI, change
- ixekizumab
- -9.6 vs -1.7−7.9 vs placeboNCT01646177
12 other results
- -10.2 vs -1.7 NCT01646177
- -8.6 vs 0.9 NCT03364309
- -8.9 vs 0.9 NCT03364309
- -10.7 vs -1 NCT01474512
- -11.1 vs -1 NCT01474512
- -9.4 vs -2 NCT01597245
- -10.4 vs -2 NCT01597245
- -9.7 vs -1.4 NCT02718898
- -8.2 vs -1.2 NCT01107457
- -8.4 vs -1.2 NCT01107457
- -6.6 vs -1.2 NCT01107457
- -6.3 vs -1.2 NCT01107457
- secukinumab
- -13.2 vs -2.0−11.2 vs placeboNCT03589885
1 other result
- -9.4 vs -0.5 NCT02690701
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
27 other shared endpoints and safety
Coverage. ixekizumab: 31 of 31 rows · secukinumab: 31 of 31 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ixekizumab Rows use multiple source trials | secukinumab Rows use multiple source trials |
|---|---|---|
| BSA Involvement absolute value · percentage points Induction | -22.4% (n=428) vs 1.3% (n=426) placebo @ 12wkQ2Wa,b,c NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 1 more dose-21.4% (n=425) vs 1.3% (n=426) placebo @ 12wkQ4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 | 5.2% (n=105) vs 13.7% (n=95) Fumaric Acid @ 12wkb,c NCT02474082 · Phase 3 · registry result, not featured evidence |
| DLQI absolute change · score Maintenance | -13.08 vs -5.37 Fumaric Acid Esters score @ 24wkb,c,d NCT02634801 · Phase 3 · registry result, not featured evidence | -12.44 vs -14.33 placebo score @ 52wk300 mgb,c,d NCT03589885 · Phase 3 1 other source trial-10 vs -9.72 placebo score @ 52wk NCT02409667 · Phase 3 · registry result, not featured evidence |
| DLQI absolute change · score No placebo or comparator arm | -9.6 score @ 52wk80 mgb,c NCT01624233 · Phase 3 · registry result, not featured evidence 3 other source trials-10.23 score @ 52wk80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence -9.7 score @ 52wk80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence -9.97 score @ 52wk80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence | -12.7 score @ 52wka,b,c NCT02409667 · Phase 3 · registry result, not featured evidence show 1 more dose-11.4 score @ 52wk NCT02409667 · Phase 3 · registry result, not featured evidence |
| DLQI 0/1 responder rate · % of participants Induction | 61% (n=136) vs 44.6% (n=166) Ustekinumab @ 12wkb,c NCT02561806 · Phase 3 · registry result, not featured evidence | 58.8% (n=245) vs 10.3% (n=247) placebo @ 12wk300 mga,b,c NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 show 1 more dose46.1% (n=245) vs 10.3% (n=247) placebo @ 12wk150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 |
| DLQI 0/1 responder rate · % of participants Maintenance | 63% (n=54) vs 14.8% (n=54) Fumaric Acid Esters @ 24wkb,c NCT02634801 · Phase 3 · registry result, not featured evidence | 64.6% (n=245) vs 50% (n=18) placebo @ 24wk300 mga,b,c NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 show 3 more doses67.3% (n=105) vs 50% (n=18) placebo @ 24wk300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 54.7% (n=245) vs 50% (n=18) placebo @ 24wk150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 53.7% (n=108) vs 50% (n=18) placebo @ 24wk150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 |
| DLQI 0/1 responder rate · % of participants No placebo or comparator arm | 74% (n=611) @ 52wk80 mg Q2Wa,b,c,e NCT02513550 · Phase 3 · registry result, not featured evidence show 2 more doses66.1% (n=310) @ 52wk80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 70.3% (n=306) @ 52wk80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence | 58.9% (n=163) @ 32wk*300 mg s.c. (2-weekly)a,b,c,e NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 96 participants with DLQI score 0/1 as posted show 1 more dose50.6% (n=162) @ 32wk*300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence · converted to % from 82 participants with DLQI score 0/1 as posted |
| Itch NRS absolute change · score No placebo or comparator arm | -4.9 score @ 192wk80 mgf,b,c,g NCT01624233 · Phase 3 · registry result, not featured evidence | 3 score @ 4wkf,b,c,g NCT04717466 · Phase 4 · registry result, not featured evidence |
| PASI percent change · % of baseline Induction | 87.12% (n=26) vs 16.22% (n=23) placebo @ 12wk150 mga,h,b,c NCT01107457 · Phase 2 · registry result, not featured evidence show 3 more doses85.69% (n=29) vs 16.22% (n=23) placebo @ 12wk75 mg NCT01107457 · Phase 2 · registry result, not featured evidence 78.48% (n=29) vs 16.22% (n=23) placebo @ 12wk25 mg NCT01107457 · Phase 2 · registry result, not featured evidence 49.33% (n=27) vs 16.22% (n=23) placebo @ 12wk10 mg NCT01107457 · Phase 2 · registry result, not featured evidence | -87.72% (n=245) vs -5.89% (n=247) placebo @ 12wk300 mga,h,b,c NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 show 1 more dose-80.87% (n=245) vs -5.89% (n=247) placebo @ 12wk150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 |
| PASI absolute change · score Induction | 15.38 vs 3.5 placebo score @ 12wk150 mga,h,b,c NCT01107457 · Phase 2 · registry result, not featured evidence show 3 more doses14.99 vs 3.5 placebo score @ 12wk75 mg NCT01107457 · Phase 2 · registry result, not featured evidence 13.56 vs 3.5 placebo score @ 12wk25 mg NCT01107457 · Phase 2 · registry result, not featured evidence 8.2 vs 3.5 placebo score @ 12wk10 mg NCT01107457 · Phase 2 · registry result, not featured evidence | -17.9 vs 0.5 placebo score @ 12wk300 mga,h,b,c NCT01555125 · Phase 3 show 1 more dose-16.33 vs 0.5 placebo score @ 12wk150 mg NCT01555125 · Phase 3 |
| PASI absolute change · score Maintenance | -16.68 vs -4.93 Fumaric Acid Esters score @ 24wkb,c,d NCT02634801 · Phase 3 · registry result, not featured evidence | -25.75 vs -21.16 Etanercept score @ 52wkhigh dosea,b,c,d NCT02471144 · Phase 3 show 1 more dose-25.26 vs -21.16 Etanercept score @ 52wklow dose NCT02471144 · Phase 3 |
| PASI absolute change · score No placebo or comparator arm | -19.41 score @ 52wk80 mg Q2Wa,b,c NCT02513550 · Phase 3 · registry result, not featured evidence show 2 more doses-18.34 score @ 52wk80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence -18.95 score @ 52wk80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence | -18.7 score @ 52wk300 mga,b,c NCT01555125 · Phase 3 show 1 more dose-16.9 score @ 52wk150 mg NCT01555125 · Phase 3 |
| PASI percent change · % of baseline No placebo or comparator arm | 96.25% (n=538) @ 52wk80 mg Q2Wa,f,b,c,i NCT02513550 · Phase 3 · registry result, not featured evidence show 2 more doses91.09% (n=274) @ 52wk80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 94.24% (n=268) @ 52wk80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence | -65.64% (n=34) @ 4wk300 mgf,b,c,i NCT02547714 · Phase 4 · registry result, not featured evidence |
| PASI 100 responder rate · % of participants Induction PASI 100 | 40.7% (n=59) vs 1.5% (n=67) placebo @ 12wkQ2Wa,j,c NCT01695239 · Phase 3 show 1 more dose31.5% (n=73) vs 1.5% (n=67) placebo @ 12wkQ4W NCT01695239 · Phase 3 | 26.7% (n=60) vs 0% (n=61) placebo @ 12wk300 mga,j,c NCT01636687 · Phase 3 show 1 more dose16.7% (n=61) vs 0% (n=61) placebo @ 12wk150 mg NCT01636687 · Phase 3 |
| PASI 100 responder rate · % of participants Maintenance | 50% (n=520) vs 52.3% (n=507) Guselkumab @ 24wkk,b,c NCT03573323 · Phase 4 · registry result, not featured evidence 1 other source trial40.7% (n=54) vs 3.7% (n=54) Fumaric Acid Esters @ 24wk NCT02634801 · Phase 3 · registry result, not featured evidence | 43.8% (n=105) vs 3.2% (n=95) Fumaric Acid @ 24wkk,b,c NCT02474082 · Phase 3 · registry result, not featured evidence |
| PASI 50 responder rate · % of participants Induction | 27.5% (n=520) vs 9.3% (n=507) Guselkumab @ 1wkk,b,c NCT03573323 · Phase 4 · registry result, not featured evidence | 9.5% (n=105) vs 1.1% (n=95) Fumaric Acid @ 1wkk,b,c NCT02474082 · Phase 3 · registry result, not featured evidence |
| PASI 75 responder rate · % of participants Induction PASI 75 | 69.5% (n=59) vs 7.5% (n=67) placebo @ 12wkQ2Wa,j,c NCT01695239 · Phase 3 show 1 more dose75.3% (n=73) vs 7.5% (n=67) placebo @ 12wkQ4W NCT01695239 · Phase 3 | 86.7% (n=60) vs 3.3% (n=61) placebo @ 12wk300 mga,j,c NCT01636687 · Phase 3 show 1 more dose71.7% (n=60) vs 3.3% (n=61) placebo @ 12wk150 mg NCT01636687 · Phase 3 |
| PASI 75 responder rate · % of participants Maintenance | 90.7% (n=54) vs 22.2% (n=54) Fumaric Acid Esters @ 24wkb,c NCT02634801 · Phase 3 · registry result, not featured evidence | 89.52% (n=105) vs 33.68% (n=95) Fumaric Acid @ 24wkb,c NCT02474082 · Phase 3 · registry result, not featured evidence |
| PASI 75 responder rate · % of participants Maintenance PASI 75 | 80.4% (n=49) vs 10.9% (n=38) placebo @ 24wkQ2Wa,j,c,d NCT01695239 · Phase 3 show 1 more dose71.2% (n=60) vs 10.9% (n=38) placebo @ 24wkQ4W NCT01695239 · Phase 3 | 71.2% (n=104) vs 88.9% (n=90) placebo @ 52wk*j,c,d PASI 75 NCT02409667 · Phase 3 · registry result, not featured evidence · converted to % from 74 Participants as posted |
| PASI 75 responder rate · % of participants No placebo or comparator arm | 95.9% (n=78) @ 24wk80 mgb,c NCT01624233 · Phase 3 · registry result, not featured evidence | 61.7% (n=107) @ 24wk300 mga,b,c NCT01961609 · Phase 3 · registry result, not featured evidence show 2 more doses68.2% (n=66) @ 24wk150 mg NCT01961609 · Phase 3 · registry result, not featured evidence 13.5% (n=37) @ 24wk150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence |
| PASI 90 responder rate · % of participants Induction PASI 90 | 57.6% (n=59) vs 1.5% (n=67) placebo @ 12wkQ2Wa,j,c NCT01695239 · Phase 3 show 1 more dose52.1% (n=73) vs 1.5% (n=67) placebo @ 12wkQ4W NCT01695239 · Phase 3 | 55% (n=60) vs 0% (n=61) placebo @ 12wk300 mga,j,c NCT01636687 · Phase 3 show 1 more dose40% (n=61) vs 0% (n=61) placebo @ 12wk150 mg NCT01636687 · Phase 3 |
| PASI 90 responder rate · % of participants Maintenance | 79.6% (n=54) vs 9.3% (n=54) Fumaric Acid Esters @ 24wkb,c NCT02634801 · Phase 3 · registry result, not featured evidence | 75.2% (n=105) vs 18.9% (n=95) Fumaric Acid @ 24wkb,c NCT02474082 · Phase 3 · registry result, not featured evidence |
| PASI 90 responder rate · % of participants No placebo or comparator arm | 79.5% (n=611) @ 52wk80 mg Q2Wa,f,b,c NCT02513550 · Phase 3 · registry result, not featured evidence show 2 more doses65.2% (n=310) @ 52wk80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 73.9% (n=306) @ 52wk80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence | 57.4% (n=54) @ 52wk*300 mgf,b,c NCT03055494 · Phase 4 · registry result, not featured evidence · converted to % from 31 Participants as posted |
| PPASI absolute change · score Induction | -5.11 vs 6.89 placebo score @ 12wkb,c NCT03073200 · Phase 3 7 other source trials-7.78 vs -2.99 placebo score @ 12wk80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence -6.34 vs -2.99 placebo score @ 12wk80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence -10.31 vs -8.34 Ustekinumab score @ 12wk NCT02561806 · Phase 3 · registry result, not featured evidence -6.4 vs -1 placebo score @ 12wk10 mg NCT01107457 · Phase 2 · registry result, not featured evidence -12.8 vs -1 placebo score @ 12wk150 mg NCT01107457 · Phase 2 · registry result, not featured evidence -4.6 vs -1 placebo score @ 12wk25 mg NCT01107457 · Phase 2 · registry result, not featured evidence -3.4 vs -1 placebo score @ 12wk75 mg NCT01107457 · Phase 2 · registry result, not featured evidence | -12.83 vs -3.07 placebo score @ 12wk300 mga,b,c NCT01806597 · Phase 3 · registry result, not featured evidence show 1 more dose-10.15 vs -3.07 placebo score @ 12wk150 mg NCT01806597 · Phase 3 · registry result, not featured evidence |
| PPASI absolute change · score Maintenance | -7.23 vs -2.45 Fumaric Acid Esters score @ 24wkb,c,l NCT02634801 · Phase 3 · registry result, not featured evidence | -17.43 vs -11.4 placebo score @ 32wk300 mga,b,c,l NCT01806597 · Phase 3 · registry result, not featured evidence show 1 more dose-16.29 vs -11.4 placebo score @ 32wk150 mg NCT01806597 · Phase 3 · registry result, not featured evidence |
| PPASI absolute change · score No placebo or comparator arm | -9 score @ 52wk80 mg Q2Wa,b,c,m NCT02513550 · Phase 3 · registry result, not featured evidence show 2 more doses-9.55 score @ 52wk80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence -9.37 score @ 52wk80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence | -19.16 score @ 132wk300 mga,b,c,m NCT01806597 · Phase 3 · registry result, not featured evidence show 1 more dose-16.74 score @ 132wk150 mg NCT01806597 · Phase 3 · registry result, not featured evidence |
| PPASI 75 responder rate · % of participants Induction | 75% (n=96) vs 35.2% (n=54) placebo @ 12wk*80 mg every 2 weeksa,b,c NCT01646177 · Phase 3 · converted to % from 72 Participants as posted show 1 more dose79.3% (n=87) vs 35.2% (n=54) placebo @ 12wk*80 mg every 4 weeks NCT01646177 · Phase 3 · converted to % from 69 Participants as posted | 23.9% (n=79) vs 10.1% (n=78) placebo @ 12wk300 mga,b,c NCT02008890 · Phase 3 · registry result, not featured evidence show 1 more dose14.7% (n=80) vs 10.1% (n=78) placebo @ 12wk150 mg NCT02008890 · Phase 3 · registry result, not featured evidence |
| PSSI absolute change · score Induction | -19.2 vs -1.8 placebo score @ 12wkQ2Wa,b,c NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 1 more dose-18.3 vs -1.8 placebo score @ 12wkQ4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 | -25.47 vs -5.98 placebo score @ 12wkb,c NCT02267135 · Phase 3 |
| Dropout rate | —Ixe Long-Term Extensionn NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 93 more results4.2%Q2W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 5.6%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q12W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Placebo Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Total Ixe Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Ixe Long-Term Extension NCT01597245 · Phase 3 · Psoriasis · phase 3 2.6%Q2W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 5.5%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —ETN/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —ETN/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 0.9%IXEQ4W (Double-Blinded Treatment P NCT03073200 · Phase 3 —IXEQ4W (Randomized Withdrawal Peri NCT03073200 · Phase 3 —IXEQ4W/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe NCT03073200 · Phase 3 —IXEQ4W_Re-Treatment (Randomized Wi NCT03073200 · Phase 3 —PBO/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —PBO/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 6.8%Q2W NCT01695239 · Phase 3 9.3%Q4W NCT01695239 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 5.7%80 mg every 2 weeks NCT01646177 · Phase 3 6.7%80 mg every 4 weeks NCT01646177 · Phase 3 6%Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence 6%Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence —Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 20%Ixekizumab - Erythrodermic Psorias NCT03942042 · Phase 4 · registry result, not featured evidence 14.3%Ixekizumab - Generalized Pustular NCT03942042 · Phase 4 · registry result, not featured evidence 10.6% NCT03573323 · Phase 4 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0.6%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 2.3%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02718898 · Phase 3 · registry result, not featured evidence 7.4%Ixekizumab NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab-Extension Period NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab-Treatment Period NCT02634801 · Phase 3 · registry result, not featured evidence 3.7%Ixekizumab NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Induction NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Maintenance NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Post Treatment Follow NCT02561806 · Phase 3 · registry result, not featured evidence 1.1%80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence 12.1%80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 11.6%80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 12.4%80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02387801 · Phase 3 · registry result, not featured evidence 0%Q2W NCT02387801 · Phase 3 · registry result, not featured evidence —Q2W NCT02387801 · Phase 3 · registry result, not featured evidence 0%Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 7.8%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 5.9%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 3.6%150 mg NCT01107457 · Phase 2 · registry result, not featured evidence 10.3%75 mg NCT01107457 · Phase 2 · registry result, not featured evidence 3.3%25 mg NCT01107457 · Phase 2 · registry result, not featured evidence 25%10 mg NCT01107457 · Phase 2 · registry result, not featured evidence —80mg Q2W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence —80mg Q4W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence 0%Single Dose NCT03073213 · Phase 1 · registry result, not featured evidence — NCT02993471 · Phase 1 · registry result, not featured evidence · combination | 4.6%300mgo NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 show 95 more results—300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 3.7%150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 2.9%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 6.1%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 5.1%300 mg NCT01555125 · Phase 3 —300 mg NCT01555125 · Phase 3 1.7%150 mg NCT01555125 · Phase 3 —150 mg NCT01555125 · Phase 3 0%300 mg NCT01636687 · Phase 3 —300 mg NCT01636687 · Phase 3 4.9%150 mg NCT01636687 · Phase 3 —150 mg NCT01636687 · Phase 3 —300 mg NCT02267135 · Phase 3 2%Secukinumab NCT02267135 · Phase 3 —300 mg (2x1mL PFS) NCT02748863 · Phase 3 —300 mg (2mL PFS) NCT02748863 · Phase 3 0%2 mL PFS NCT02748863 · Phase 3 —2 mL PFS NCT02748863 · Phase 3 2.8%2 x 1 mL PFS NCT02748863 · Phase 3 —2 x 1 mL PFS NCT02748863 · Phase 3 —300 mg NCT03589885 · Phase 3 0% NCT04717466 · Phase 4 · registry result, not featured evidence —300 mg NCT03020199 · Phase 4 · registry result, not featured evidence —300 mg NCT03020199 · Phase 4 · registry result, not featured evidence 18.5%300 mg NCT03055494 · Phase 4 · registry result, not featured evidence 13.3% NCT02592018 · Phase 4 · registry result, not featured evidence —300 mg NCT02690701 · Phase 4 · registry result, not featured evidence 4.3%Secukinumab NCT02690701 · Phase 4 · registry result, not featured evidence 0%300 mg NCT02547714 · Phase 4 · registry result, not featured evidence —Entire Period - Secukinumab (AIN45 NCT02547714 · Phase 4 · registry result, not featured evidence —Induction Period - Secukinumab (AI NCT02547714 · Phase 4 · registry result, not featured evidence 14.3%AIN457 High Dose NCT03668613 · Phase 3 · registry result, not featured evidence 26.2%AIN457 Low Dose NCT03668613 · Phase 3 · registry result, not featured evidence 10.3%300 mg every 2 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 13.3%300 mg every 4 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 9.7%300 mg every 4 weeks (up-titration) NCT03504852 · Phase 3 · registry result, not featured evidence —300 mg NCT03066609 · Phase 3 · registry result, not featured evidence 0.7%300 mg NCT03066609 · Phase 3 · registry result, not featured evidence —150 mg NCT03066609 · Phase 3 · registry result, not featured evidence 1.5%150 mg NCT03066609 · Phase 3 · registry result, not featured evidence —300 mg NCT02826603 · Phase 3 · registry result, not featured evidence 11.1%300 mg NCT02826603 · Phase 3 · registry result, not featured evidence 4.7%300 mg NCT01544595 · Phase 3 · registry result, not featured evidence 13%150 mg NCT01544595 · Phase 3 · registry result, not featured evidence 7.7%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 7%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 19%300 mg NCT02008890 · Phase 3 · registry result, not featured evidence —300 mg NCT02008890 · Phase 3 · registry result, not featured evidence 18.8%150 mg NCT02008890 · Phase 3 · registry result, not featured evidence —150 mg NCT02008890 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 1 NCT02409667 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 2 NCT02409667 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 3 NCT02409667 · Phase 3 · registry result, not featured evidence 25%300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 48.5%300 mg open-label NCT01640951 · Phase 3 · registry result, not featured evidence 78.3%300 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence 16.1%300 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 20%150 mg fixed interval then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 13.7%150 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 81.8%150 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence 59.7%150 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg NCT02595970 · Phase 3 · registry result, not featured evidence 16.7%Single Arm Secukinumab NCT02595970 · Phase 3 · registry result, not featured evidence 1.5%300 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled 6%150 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled 7.2%300 mg NCT01806597 · Phase 3 · registry result, not featured evidence 7.4%150 mg NCT01806597 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 3%300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence — NCT02362789 · Phase 3 · registry result, not featured evidence 10.1%300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —300 mg NCT01961609 · Phase 3 · registry result, not featured evidence 11.2%150 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg NCT01961609 · Phase 3 · registry result, not featured evidence 15.1%300 mg NCT02074982 · Phase 3 · registry result, not featured evidence 5.7% NCT02474082 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —Ixe Long-Term Extensionn NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 93 more results2.3%Q2W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 2.3%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q12W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Placebo Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Total Ixe Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Ixe Long-Term Extension NCT01597245 · Phase 3 · Psoriasis · phase 3 1.1%Q2W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 1.4%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —ETN/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —ETN/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 —IXEQ4W (Double-Blinded Treatment P NCT03073200 · Phase 3 —IXEQ4W (Randomized Withdrawal Peri NCT03073200 · Phase 3 —IXEQ4W/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe NCT03073200 · Phase 3 —IXEQ4W_Re-Treatment (Randomized Wi NCT03073200 · Phase 3 —PBO/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —PBO/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 2.9%Q2W NCT01695239 · Phase 3 1.9%Q4W NCT01695239 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 2.1%80 mg every 2 weeks NCT01646177 · Phase 3 2.3%80 mg every 4 weeks NCT01646177 · Phase 3 —Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence —Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 20%Ixekizumab - Erythrodermic Psorias NCT03942042 · Phase 4 · registry result, not featured evidence 0%Ixekizumab - Generalized Pustular NCT03942042 · Phase 4 · registry result, not featured evidence 2.9% NCT03573323 · Phase 4 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0.6%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02718898 · Phase 3 · registry result, not featured evidence 3.7%Ixekizumab NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab-Extension Period NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab-Treatment Period NCT02634801 · Phase 3 · registry result, not featured evidence 1.5%Ixekizumab NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Induction NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Maintenance NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Post Treatment Follow NCT02561806 · Phase 3 · registry result, not featured evidence 1.1%80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence 2.8%80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 1.6%80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 4.2%80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —Q2W NCT02387801 · Phase 3 · registry result, not featured evidence —Q2W NCT02387801 · Phase 3 · registry result, not featured evidence —Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 1%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 2%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01107457 · Phase 2 · registry result, not featured evidence 0%75 mg NCT01107457 · Phase 2 · registry result, not featured evidence 3.3%25 mg NCT01107457 · Phase 2 · registry result, not featured evidence 7.1%10 mg NCT01107457 · Phase 2 · registry result, not featured evidence —80mg Q2W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence —80mg Q4W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence —Single Dose NCT03073213 · Phase 1 · registry result, not featured evidence — NCT02993471 · Phase 1 · registry result, not featured evidence · combination | 1.2%300mgo NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 show 95 more results—300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 0.6%150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 1.2%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 2%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 1.7%300 mg NCT01555125 · Phase 3 —300 mg NCT01555125 · Phase 3 0%150 mg NCT01555125 · Phase 3 —150 mg NCT01555125 · Phase 3 0%300 mg NCT01636687 · Phase 3 —300 mg NCT01636687 · Phase 3 1.6%150 mg NCT01636687 · Phase 3 —150 mg NCT01636687 · Phase 3 —300 mg NCT02267135 · Phase 3 —Secukinumab NCT02267135 · Phase 3 —300 mg (2x1mL PFS) NCT02748863 · Phase 3 —300 mg (2mL PFS) NCT02748863 · Phase 3 0%2 mL PFS NCT02748863 · Phase 3 —2 mL PFS NCT02748863 · Phase 3 1.4%2 x 1 mL PFS NCT02748863 · Phase 3 —2 x 1 mL PFS NCT02748863 · Phase 3 —300 mg NCT03589885 · Phase 3 — NCT04717466 · Phase 4 · registry result, not featured evidence —300 mg NCT03020199 · Phase 4 · registry result, not featured evidence —300 mg NCT03020199 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03055494 · Phase 4 · registry result, not featured evidence 6.7% NCT02592018 · Phase 4 · registry result, not featured evidence —300 mg NCT02690701 · Phase 4 · registry result, not featured evidence 4.3%Secukinumab NCT02690701 · Phase 4 · registry result, not featured evidence —300 mg NCT02547714 · Phase 4 · registry result, not featured evidence —Entire Period - Secukinumab (AIN45 NCT02547714 · Phase 4 · registry result, not featured evidence —Induction Period - Secukinumab (AI NCT02547714 · Phase 4 · registry result, not featured evidence 4.8%AIN457 High Dose NCT03668613 · Phase 3 · registry result, not featured evidence 2.4%AIN457 Low Dose NCT03668613 · Phase 3 · registry result, not featured evidence 2.4%300 mg every 2 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 5.9%300 mg every 4 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 6.5%300 mg every 4 weeks (up-titration) NCT03504852 · Phase 3 · registry result, not featured evidence —300 mg NCT03066609 · Phase 3 · registry result, not featured evidence 0.7%300 mg NCT03066609 · Phase 3 · registry result, not featured evidence —150 mg NCT03066609 · Phase 3 · registry result, not featured evidence 1.5%150 mg NCT03066609 · Phase 3 · registry result, not featured evidence —300 mg NCT02826603 · Phase 3 · registry result, not featured evidence 3.1%300 mg NCT02826603 · Phase 3 · registry result, not featured evidence 0.6%300 mg NCT01544595 · Phase 3 · registry result, not featured evidence 1%150 mg NCT01544595 · Phase 3 · registry result, not featured evidence 3.7%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 3.8%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 10.1%300 mg NCT02008890 · Phase 3 · registry result, not featured evidence —300 mg NCT02008890 · Phase 3 · registry result, not featured evidence 7.5%150 mg NCT02008890 · Phase 3 · registry result, not featured evidence —150 mg NCT02008890 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 1 NCT02409667 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 2 NCT02409667 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 3 NCT02409667 · Phase 3 · registry result, not featured evidence 6%300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 9.1%300 mg open-label NCT01640951 · Phase 3 · registry result, not featured evidence 18.3%300 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence 0.9%300 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 4%150 mg fixed interval then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 1.1%150 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 10.9%150 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence 10.4%150 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg NCT02595970 · Phase 3 · registry result, not featured evidence 4.2%Single Arm Secukinumab NCT02595970 · Phase 3 · registry result, not featured evidence 0%300 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled 3%150 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled 1.4%300 mg NCT01806597 · Phase 3 · registry result, not featured evidence 1.5%150 mg NCT01806597 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 1%300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence — NCT02362789 · Phase 3 · registry result, not featured evidence 2.5%300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —300 mg NCT01961609 · Phase 3 · registry result, not featured evidence 4.3%150 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg NCT01961609 · Phase 3 · registry result, not featured evidence 4.5%300 mg NCT02074982 · Phase 3 · registry result, not featured evidence 1.9% NCT02474082 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 12.7%Ixe Long-Term Extensionn NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 93 more results1.6%Q2W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 2.8%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 3.2%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 10.3%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 4.8%Q12W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 6.1%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 3.8%Placebo Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 6.1%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 4.8%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 12.5%Total Ixe Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 4.5%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 10.9%Ixe Long-Term Extension NCT01597245 · Phase 3 · Psoriasis · phase 3 1.4%Q2W NCT01597245 · Phase 3 · Psoriasis · phase 3 4.1%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 2.3%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 5.3%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 8.4%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 3.6%ETN/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 0%ETN/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 0.9%IXEQ4W (Double-Blinded Treatment P NCT03073200 · Phase 3 8.8%IXEQ4W (Randomized Withdrawal Peri NCT03073200 · Phase 3 6.2%IXEQ4W/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 2.9%IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe NCT03073200 · Phase 3 0%IXEQ4W_Re-Treatment (Randomized Wi NCT03073200 · Phase 3 5.7%PBO/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 0%PBO/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 0%Q2W NCT01695239 · Phase 3 0%Q4W NCT01695239 · Phase 3 10.4%Q2W NCT01695239 · Phase 3 15%Q4W NCT01695239 · Phase 3 5.6%Q2W NCT01695239 · Phase 3 2.9%Q4W NCT01695239 · Phase 3 2.3%80 mg every 2 weeks NCT01646177 · Phase 3 1.6%80 mg every 4 weeks NCT01646177 · Phase 3 —Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence 0.5%Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 0%Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - Erythrodermic Psorias NCT03942042 · Phase 4 · registry result, not featured evidence —Ixekizumab - Generalized Pustular NCT03942042 · Phase 4 · registry result, not featured evidence 3.5% NCT03573323 · Phase 4 · registry result, not featured evidence 4.3%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 2%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 2%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 4.4%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0.6%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 5.4%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 2.1%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 2.3%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 1.9%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 1.1%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q2W NCT02718898 · Phase 3 · registry result, not featured evidence —Ixekizumab NCT02634801 · Phase 3 · registry result, not featured evidence 6.3%Ixekizumab-Extension Period NCT02634801 · Phase 3 · registry result, not featured evidence 1.9%Ixekizumab-Treatment Period NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab NCT02561806 · Phase 3 · registry result, not featured evidence 1.5%Ixekizumab - Induction NCT02561806 · Phase 3 · registry result, not featured evidence 5.3%Ixekizumab - Maintenance NCT02561806 · Phase 3 · registry result, not featured evidence 0%Ixekizumab - Post Treatment Follow NCT02561806 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence 4.4%80 mg NCT01624233 · Phase 3 · registry result, not featured evidence 11.3%80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 5.3%80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 0%80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 5.2%80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 20%80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 5.2%80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —Q2W NCT02387801 · Phase 3 · registry result, not featured evidence 0%Q2W NCT02387801 · Phase 3 · registry result, not featured evidence —Q4W NCT02387801 · Phase 3 · registry result, not featured evidence 0%Q4W NCT02387801 · Phase 3 · registry result, not featured evidence 4.9%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 3.9%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 2.9%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01107457 · Phase 2 · registry result, not featured evidence 0%75 mg NCT01107457 · Phase 2 · registry result, not featured evidence 3.3%25 mg NCT01107457 · Phase 2 · registry result, not featured evidence 3.6%10 mg NCT01107457 · Phase 2 · registry result, not featured evidence 7.1%80mg Q2W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence 0%80mg Q4W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence 0%Single Dose NCT03073213 · Phase 1 · registry result, not featured evidence 0% NCT02993471 · Phase 1 · registry result, not featured evidence · combination | —300mgo NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 show 95 more results6.4%300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 1.2%300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 5.5%150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 2.1%150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 6.9%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 5.4%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 2.1%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 2.4%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 6.1%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 5.4%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 1.7%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 1.6%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01555125 · Phase 3 5.1%300 mg NCT01555125 · Phase 3 —150 mg NCT01555125 · Phase 3 1.7%150 mg NCT01555125 · Phase 3 —300 mg NCT01636687 · Phase 3 1.7%300 mg NCT01636687 · Phase 3 —150 mg NCT01636687 · Phase 3 4.9%150 mg NCT01636687 · Phase 3 0%300 mg NCT02267135 · Phase 3 —Secukinumab NCT02267135 · Phase 3 1.4%300 mg (2x1mL PFS) NCT02748863 · Phase 3 0%300 mg (2mL PFS) NCT02748863 · Phase 3 —2 mL PFS NCT02748863 · Phase 3 —2 mL PFS NCT02748863 · Phase 3 —2 x 1 mL PFS NCT02748863 · Phase 3 —2 x 1 mL PFS NCT02748863 · Phase 3 2.4%300 mg NCT03589885 · Phase 3 10% NCT04717466 · Phase 4 · registry result, not featured evidence 5.4%300 mg NCT03020199 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03020199 · Phase 4 · registry result, not featured evidence 1.9%300 mg NCT03055494 · Phase 4 · registry result, not featured evidence 6.7% NCT02592018 · Phase 4 · registry result, not featured evidence 10.9%300 mg NCT02690701 · Phase 4 · registry result, not featured evidence —Secukinumab NCT02690701 · Phase 4 · registry result, not featured evidence —300 mg NCT02547714 · Phase 4 · registry result, not featured evidence 0%Entire Period - Secukinumab (AIN45 NCT02547714 · Phase 4 · registry result, not featured evidence 0%Induction Period - Secukinumab (AI NCT02547714 · Phase 4 · registry result, not featured evidence 4.8%AIN457 High Dose NCT03668613 · Phase 3 · registry result, not featured evidence 9.5%AIN457 Low Dose NCT03668613 · Phase 3 · registry result, not featured evidence 8.5%300 mg every 2 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 13.4%300 mg every 4 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 12.9%300 mg every 4 weeks (up-titration) NCT03504852 · Phase 3 · registry result, not featured evidence 3.3%300 mg NCT03066609 · Phase 3 · registry result, not featured evidence —300 mg NCT03066609 · Phase 3 · registry result, not featured evidence 3.7%150 mg NCT03066609 · Phase 3 · registry result, not featured evidence —150 mg NCT03066609 · Phase 3 · registry result, not featured evidence 5.3%300 mg NCT02826603 · Phase 3 · registry result, not featured evidence —300 mg NCT02826603 · Phase 3 · registry result, not featured evidence —300 mg NCT01544595 · Phase 3 · registry result, not featured evidence —150 mg NCT01544595 · Phase 3 · registry result, not featured evidence 8.5%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 5.4%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence —300 mg NCT02008890 · Phase 3 · registry result, not featured evidence 16.5%300 mg NCT02008890 · Phase 3 · registry result, not featured evidence —150 mg NCT02008890 · Phase 3 · registry result, not featured evidence 11.3%150 mg NCT02008890 · Phase 3 · registry result, not featured evidence 3.9%Treatment Period 2: Group 1 NCT02409667 · Phase 3 · registry result, not featured evidence 3.8%Treatment Period 2: Group 2 NCT02409667 · Phase 3 · registry result, not featured evidence 3.5%Treatment Period 2: Group 3 NCT02409667 · Phase 3 · registry result, not featured evidence —300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg open-label NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —150 mg fixed interval then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —150 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —150 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence —150 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 10.8%300 mg NCT02595970 · Phase 3 · registry result, not featured evidence —Single Arm Secukinumab NCT02595970 · Phase 3 · registry result, not featured evidence —300 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled —150 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled —300 mg NCT01806597 · Phase 3 · registry result, not featured evidence —150 mg NCT01806597 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 2.5%300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 4.9%300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 4.1%300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 4.8% NCT02362789 · Phase 3 · registry result, not featured evidence —300 mg NCT01961609 · Phase 3 · registry result, not featured evidence 13.4%300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence 12.2%150 mg NCT01961609 · Phase 3 · registry result, not featured evidence 12.2%300 mg NCT02074982 · Phase 3 · registry result, not featured evidence 3.8% NCT02474082 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | n nasopharyngitis 16.9% (placebo 11.5%) upper respiratory tract infection 8.4% (placebo 8%) arthralgia 5.1% (placebo 2.7%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 79 more resultsQ2W nasopharyngitis 11.3% (placebo 11.5%) injection site reaction 9.7% (placebo 0.9%) injection site erythema 6.5% (placebo 0%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 10.4% (placebo 11.5%) injection site reaction 6.3% (placebo 0.9%) upper respiratory tract infection 4.6% (placebo 8%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 10.6% (placebo 11.5%) upper respiratory tract infection 5.2% (placebo 8%) injection site reaction 3.7% (placebo 0.9%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 24.4% (placebo 11.5%) arthralgia 10.3% (placebo 2.7%) upper respiratory tract infection 10.3% (placebo 8%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q12W nasopharyngitis 18.1% (placebo 11.5%) upper respiratory tract infection 8.8% (placebo 8%) headache 7% (placebo 2.2%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 22.3% (placebo 11.5%) upper respiratory tract infection 7.9% (placebo 8%) arthralgia 5.7% (placebo 2.7%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 nasopharyngitis 15.4% (placebo 11.5%) influenza 7.7% (placebo 1.8%) upper respiratory tract infection 7.7% (placebo 8%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 19.7% (placebo 11.5%) upper respiratory tract infection 13.6% (placebo 8%) injection site reaction 9.2% (placebo 0.9%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 17.7% (placebo 11.5%) back pain 9.7% (placebo 3.1%) upper respiratory tract infection 6.5% (placebo 8%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 nasopharyngitis 16.6% (placebo 11.5%) upper respiratory tract infection 8.3% (placebo 8%) arthralgia 5% (placebo 2.7%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 17.5% (placebo 14.4%) upper respiratory tract infection 10.5% (placebo 6.1%) injection site reaction 10% (placebo 0.8%) NCT01597245 · Phase 3 · Psoriasis · phase 3 nasopharyngitis 12.8% (placebo 14.4%) upper respiratory tract infection 11% (placebo 6.1%) arthralgia 4.9% (placebo 6.1%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q2W injection site reaction 11.4% (placebo 0.8%) nasopharyngitis 9.7% (placebo 14.4%) upper respiratory tract infection 5.7% (placebo 6.1%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q4W nasopharyngitis 16.3% (placebo 14.4%) upper respiratory tract infection 14.3% (placebo 6.1%) headache 8.2% (placebo 3.8%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q4W nasopharyngitis 8.1% (placebo 14.4%) injection site reaction 5.5% (placebo 0.8%) headache 4.9% (placebo 3.8%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q4W nasopharyngitis 16% (placebo 14.4%) upper respiratory tract infection 9.3% (placebo 6.1%) vulvovaginal candidiasis 9.1% (placebo 0%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q4W nasopharyngitis 18.7% (placebo 14.4%) upper respiratory tract infection 12.9% (placebo 6.1%) injection site reaction 6.5% (placebo 0.8%) NCT01597245 · Phase 3 · Psoriasis · phase 3 nasopharyngitis 14.3% (placebo 7.1%) pharyngitis 14.3% (placebo 0%) tonsillitis 14.3% (placebo 3.6%) NCT03073200 · Phase 3 acne 11.1% (placebo 1.8%) headache 11.1% (placebo 1.8%) influenza 11.1% (placebo 0%) NCT03073200 · Phase 3 nasopharyngitis 11.3% (placebo 7.1%) headache 10.4% (placebo 1.8%) injection site reaction 9.6% (placebo 0%) NCT03073200 · Phase 3 nasopharyngitis 32.4% (placebo 7.1%) tonsillitis 8.8% (placebo 3.6%) viral upper respiratory tract infection 8.8% (placebo 0%) NCT03073200 · Phase 3 injection site reaction 17.7% (placebo 0%) nasopharyngitis 14.2% (placebo 7.1%) upper respiratory tract infection 11.5% (placebo 7.1%) NCT03073200 · Phase 3 upper respiratory tract infection 16.2% (placebo 7.1%) nasopharyngitis 11.8% (placebo 7.1%) headache 8.8% (placebo 1.8%) NCT03073200 · Phase 3 diarrhoea 6.1% (placebo 1.8%) nasopharyngitis 6.1% (placebo 7.1%) pharyngitis 6.1% (placebo 0%) NCT03073200 · Phase 3 injection site reaction 15.1% (placebo 0%) nasopharyngitis 13.2% (placebo 7.1%) upper respiratory tract infection 9.4% (placebo 7.1%) NCT03073200 · Phase 3 upper respiratory tract infection 29.4% (placebo 7.1%) bronchitis 8.8% (placebo 0%) pharyngitis 8.8% (placebo 0%) NCT03073200 · Phase 3 Q2W back pain 0% (placebo 0%) bronchitis 0% (placebo 2.8%) injection site erythema 0% (placebo 0%) NCT01695239 · Phase 3 Q4W back pain 0% (placebo 0%) bronchitis 0% (placebo 2.8%) injection site erythema 0% (placebo 0%) NCT01695239 · Phase 3 Q2W viral upper respiratory tract infection 11.5% (placebo 4.7%) upper respiratory tract infection 9.8% (placebo 6.6%) injection site reaction 7.1% (placebo 0%) NCT01695239 · Phase 3 Q4W upper respiratory tract infection 11.2% (placebo 6.6%) viral upper respiratory tract infection 11.2% (placebo 4.7%) injection site reaction 6.4% (placebo 0%) NCT01695239 · Phase 3 Q2W injection site reaction 12.1% (placebo 0%) injection site erythema 6.5% (placebo 0%) viral upper respiratory tract infection 5.6% (placebo 4.7%) NCT01695239 · Phase 3 Q4W injection site reaction 15.7% (placebo 0%) injection site erythema 12.7% (placebo 0%) bronchitis 2.9% (placebo 2.8%) NCT01695239 · Phase 3 80 mg every 2 weeks injection site reaction 9.6% (placebo 1.6%) nasopharyngitis 6.8% (placebo 5.7%) headache 4.2% (placebo 2.6%) NCT01646177 · Phase 3 80 mg every 4 weeks injection site reaction 11.3% (placebo 1.6%) nasopharyngitis 7.6% (placebo 5.7%) headache 4.2% (placebo 2.6%) NCT01646177 · Phase 3 Q2W/Q4W latent tuberculosis 8.6% pyrexia 8.6% injection site erythema 1.9% NCT05855967 · Phase 4 · registry result, not featured evidence Q4W latent tuberculosis 9.8% urinary tract infection 4.9% c-reactive protein increased 2.4% NCT05855967 · Phase 4 · registry result, not featured evidence injection site reaction 9.4% upper respiratory tract infection 7.7% nasopharyngitis 6.6% NCT03573323 · Phase 4 · registry result, not featured evidence 80 mg Q2W blood glucose increased 17.4% (placebo 6.3%) folliculitis 13% (placebo 5.1%) hepatic function abnormal 13% (placebo 5.1%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 31% (placebo 27.8%) injection site reaction 17% (placebo 10.1%) tinea pedis 10% (placebo 7.6%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 12% (placebo 27.8%) oropharyngeal pain 10% (placebo 2.5%) blood triglycerides increased 8% (placebo 0%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W alopecia 10% (placebo 0%) blood immunoglobulin a increased 10% (placebo 1.3%) blood urine present 10% (placebo 6.3%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 20% (placebo 27.8%) injection site reaction 11.1% (placebo 10.1%) oropharyngeal pain 11.1% (placebo 2.5%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W alopecia 0% (placebo 0%) arthralgia 0% (placebo 0%) blood glucose decreased 0% (placebo 0%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 15.9% (placebo 27.8%) injection site reaction 10.8% (placebo 10.1%) urticaria 5.7% (placebo 11.4%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 25.8% (placebo 27.8%) blood urine present 12.9% (placebo 6.3%) tinea pedis 12.9% (placebo 7.6%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 27.2% (placebo 27.8%) injection site reaction 18.5% (placebo 10.1%) tinea pedis 12% (placebo 7.6%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 14.9% (placebo 27.8%) oropharyngeal pain 8.5% (placebo 2.5%) pruritus 8.5% (placebo 2.5%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W tonsillitis 28.6% (placebo 0%) upper respiratory tract infection 28.6% (placebo 27.8%) dermatitis allergic 14.3% (placebo 5.1%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 16.3% (placebo 27.8%) injection site reaction 7% (placebo 10.1%) rhinitis 7% (placebo 1.3%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W hepatic function abnormal 1.3% (placebo 5.1%) blood glucose increased 1.1% (placebo 6.3%) upper respiratory tract infection 1.1% (placebo 27.8%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 14.4% (placebo 27.8%) injection site reaction 7.5% (placebo 10.1%) hepatic function abnormal 5.7% (placebo 5.1%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 16% (placebo 6.8%) injection site reaction 6.7% (placebo 0%) headache 4% (placebo 5.4%) NCT02718898 · Phase 3 · registry result, not featured evidence nasopharyngitis 37.5% back pain 6.3% bronchitis 4.2% NCT02634801 · Phase 3 · registry result, not featured evidence nasopharyngitis 37% headache 13% injection site reaction 13% NCT02634801 · Phase 3 · registry result, not featured evidence nasopharyngitis 17% injection site erythema 7.4% headache 5.2% NCT02561806 · Phase 3 · registry result, not featured evidence nasopharyngitis 27.5% headache 7.6% arthralgia 6.1% NCT02561806 · Phase 3 · registry result, not featured evidence 80 mg viral upper respiratory tract infection 39.6% eczema 12.1% injection site reaction 8.8% NCT01624233 · Phase 3 · registry result, not featured evidence 80 mg viral upper respiratory tract infection 20% eczema 12.5% eczema asteatotic 11.3% NCT01624233 · Phase 3 · registry result, not featured evidence 80 mg Q2W viral upper respiratory tract infection 12% upper respiratory tract infection 11.3% injection site reaction 8% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q2W viral upper respiratory tract infection 37.5% vaginal infection 25% injection site erythema 12.5% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 22.2% alanine aminotransferase increased 11.1% aspartate aminotransferase increased 11.1% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W/Q2W viral upper respiratory tract infection 17.3% upper respiratory tract infection 12.7% headache 5.2% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W/Q2W arthralgia 20% benign bone neoplasm 20% blood glucose increased 20% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 14.8% viral upper respiratory tract infection 13.2% injection site reaction 5.8% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 33.3% biopsy breast 16.7% influenza 16.7% NCT02387801 · Phase 3 · registry result, not featured evidence Q2W arthralgia 33.3% acne 16.7% hyperhidrosis 16.7% NCT02387801 · Phase 3 · registry result, not featured evidence Q4W biopsy prostate 33.3% injection site urticaria 33.3% hordeolum 16.7% NCT02387801 · Phase 3 · registry result, not featured evidence 80 mg upper respiratory tract infection 8.6% injection site reaction 4.3% NCT01777191 · Phase 3 · registry result, not featured evidence 80 mg injection site reaction 4.9% upper respiratory tract infection 4.9% NCT01777191 · Phase 3 · registry result, not featured evidence 80 mg injection site reaction 7.8% upper respiratory tract infection 3.9% NCT01777191 · Phase 3 · registry result, not featured evidence 150 mg nasopharyngitis 14.3% (placebo 18.5%) dermatitis contact 7.1% (placebo 0%) dry skin 7.1% (placebo 0%) NCT01107457 · Phase 2 · registry result, not featured evidence 75 mg nasopharyngitis 10.3% (placebo 18.5%) cough 6.9% (placebo 0%) dizziness 6.9% (placebo 0%) NCT01107457 · Phase 2 · registry result, not featured evidence 25 mg headache 13.3% (placebo 3.7%) injection site reaction 10% (placebo 0%) nasopharyngitis 10% (placebo 18.5%) NCT01107457 · Phase 2 · registry result, not featured evidence 10 mg headache 14.3% (placebo 3.7%) nasopharyngitis 10.7% (placebo 18.5%) dizziness 7.1% (placebo 0%) NCT01107457 · Phase 2 · registry result, not featured evidence 80mg Q2W Multiple Dose pruritus 42.9% upper respiratory tract infection 35.7% diarrhoea 21.4% NCT03073213 · Phase 1 · registry result, not featured evidence 80mg Q4W Multiple Dose upper respiratory tract infection 20% arthralgia 13.3% diarrhoea 13.3% NCT03073213 · Phase 1 · registry result, not featured evidence Single Dose pruritus 41.7% protein urine present 33.3% flatulence 25% NCT03073213 · Phase 1 · registry result, not featured evidence alopecia 3.7% arthralgia 3.7% back pain 3.7% NCT02993471 · Phase 1 · registry result, not featured evidence · combination | 300mgo nasopharyngitis 27.9% (placebo 8%) headache 14.4% (placebo 7.3%) diarrhoea 10.4% (placebo 2.1%) NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 show 51 more results300mg nasopharyngitis 10.7% (placebo 8%) headache 9.2% (placebo 7.3%) diarrhoea 5.2% (placebo 2.1%) NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 150mg nasopharyngitis 25.1% (placebo 8%) headache 10.4% (placebo 7.3%) diarrhoea 9.2% (placebo 2.1%) NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 150mg nasopharyngitis 13.5% (placebo 8%) headache 4.9% (placebo 7.3%) arthralgia 4.3% (placebo 3.1%) NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg nasopharyngitis 18.4% (placebo 8.1%) upper respiratory tract infection 10.6% (placebo 0.8%) headache 9% (placebo 4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg nasopharyngitis 16.3% (placebo 8.1%) upper respiratory tract infection 9.2% (placebo 0.8%) headache 8.6% (placebo 4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg arthralgia 2.1% (placebo 3.2%) blood creatinine increased 2.1% (placebo 0.4%) eczema 2.1% (placebo 0%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg nasopharyngitis 9% (placebo 8.1%) headache 4.9% (placebo 4%) pruritus 4.5% (placebo 2.4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 150 mg nasopharyngitis 21.6% (placebo 8.1%) upper respiratory tract infection 11.4% (placebo 0.8%) headache 7.8% (placebo 4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 150 mg nasopharyngitis 19.5% (placebo 8.1%) upper respiratory tract infection 10.2% (placebo 0.8%) headache 6.8% (placebo 4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 150 mg psoriasis 3.4% (placebo 3.2%) psoriatic arthropathy 3.4% (placebo 1.6%) influenza 1.7% (placebo 1.2%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 150 mg nasopharyngitis 9.4% (placebo 8.1%) headache 5.3% (placebo 4%) oropharyngeal pain 4.1% (placebo 1.2%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg diarrhoea 8.5% (placebo 1.7%) back pain 5.1% (placebo 0%) nasopharyngitis 5.1% (placebo 8.5%) NCT01555125 · Phase 3 150 mg headache 6.8% (placebo 6.8%) diarrhoea 5.1% (placebo 1.7%) nasopharyngitis 5.1% (placebo 8.5%) NCT01555125 · Phase 3 300 mg nasopharyngitis 31.7% (placebo 14.8%) pruritus 6.7% (placebo 3.3%) cough 5% (placebo 3.3%) NCT01636687 · Phase 3 150 mg nasopharyngitis 23% (placebo 14.8%) headache 8.2% (placebo 4.9%) hypertension 4.9% (placebo 6.6%) NCT01636687 · Phase 3 300 mg dermatitis contact 5.9% (placebo 3.9%) nasopharyngitis 5.9% (placebo 2%) diarrhoea 3.9% (placebo 3.9%) NCT02267135 · Phase 3 300 mg (2x1mL PFS) nasopharyngitis 11.3% (placebo 11.3%) headache 8.5% (placebo 4.2%) back pain 4.2% (placebo 2.8%) NCT02748863 · Phase 3 300 mg (2mL PFS) nasopharyngitis 9.7% (placebo 11.3%) headache 8.3% (placebo 4.2%) pruritus 6.9% (placebo 4.2%) NCT02748863 · Phase 3 300 mg nasopharyngitis 14.6% (placebo 0%) hypertension 9.8% (placebo 0%) influenza like illness 7.3% (placebo 2.5%) NCT03589885 · Phase 3 300 mg headache 9.8% nasopharyngitis 9.8% upper respiratory tract infection 7.1% NCT03020199 · Phase 4 · registry result, not featured evidence 300 mg arthralgia 5.7% nasopharyngitis 3.4% headache 1.1% NCT03020199 · Phase 4 · registry result, not featured evidence 300 mg nasopharyngitis 18.5% upper respiratory tract infection 13% back pain 7.4% NCT03055494 · Phase 4 · registry result, not featured evidence upper respiratory infection 60% cough 20% diarrhea 13.3% NCT02592018 · Phase 4 · registry result, not featured evidence 300 mg nasopharyngitis 19.6% upper respiratory tract infection 13% arthralgia 10.9% NCT02690701 · Phase 4 · registry result, not featured evidence nasopharyngitis 20.6% dermatitis contact 5.9% hypertension 5.9% NCT02547714 · Phase 4 · registry result, not featured evidence nasopharyngitis 11.8% alopecia 2.9% dermatitis contact 2.9% NCT02547714 · Phase 4 · registry result, not featured evidence covid-19 21.4% nasopharyngitis 16.7% viral upper respiratory tract infection 16.7% NCT03668613 · Phase 3 · registry result, not featured evidence nasopharyngitis 31% covid-19 26.2% acne 16.7% NCT03668613 · Phase 3 · registry result, not featured evidence 300 mg every 2 weeks nasopharyngitis 19.4% upper respiratory tract infection 7.3% headache 6.7% NCT03504852 · Phase 3 · registry result, not featured evidence 300 mg every 4 weeks nasopharyngitis 16.4% upper respiratory tract infection 6.7% oropharyngeal pain 5.2% NCT03504852 · Phase 3 · registry result, not featured evidence 300 mg every 4 weeks (up-titration) nasopharyngitis 16.1% intertrigo 9.7% neutrophil count decreased 9.7% NCT03504852 · Phase 3 · registry result, not featured evidence 300 mg upper respiratory tract infection 24.6% (placebo 9.6%) hyperuricaemia 20.6% (placebo 12.6%) nasopharyngitis 16.2% (placebo 3.7%) NCT03066609 · Phase 3 · registry result, not featured evidence 150 mg upper respiratory tract infection 30.1% (placebo 9.6%) hyperuricaemia 18.4% (placebo 12.6%) influenza 12.5% (placebo 3%) NCT03066609 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 10% upper respiratory tract infection 8.9% diarrhoea 4.7% NCT02826603 · Phase 3 · registry result, not featured evidence 300 mg viral upper respiratory tract infection 39.2% (placebo 15.4%) pustular psoriasis 20.3% (placebo 5.1%) headache 15.2% (placebo 12.8%) NCT02008890 · Phase 3 · registry result, not featured evidence 150 mg pustular psoriasis 23.8% (placebo 5.1%) viral upper respiratory tract infection 21.3% (placebo 15.4%) headache 8.8% (placebo 12.8%) NCT02008890 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 14.6% (placebo 23.7%) headache 4.8% (placebo 1.1%) back pain 2.8% (placebo 1.1%) NCT02409667 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 14.4% (placebo 23.7%) back pain 4.2% (placebo 1.1%) headache 4.1% (placebo 1.1%) NCT02409667 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20.2% (placebo 23.7%) psoriasis 9.6% (placebo 8.6%) upper respiratory tract infection 6.1% (placebo 5.4%) NCT02409667 · Phase 3 · registry result, not featured evidence 300 mg back pain 10.8% nasopharyngitis 10.8% diarrhoea 10% NCT02595970 · Phase 3 · registry result, not featured evidence 300 mg s.c. (2-weekly) nasopharyngitis 16.6% headache 3.1% hypertension 2.5% NCT02474069 · Phase 3 · registry result, not featured evidence 300 mg s.c. (4-weekly) nasopharyngitis 14.2% headache 3.1% arthralgia 2.5% NCT02474069 · Phase 3 · registry result, not featured evidence 300 mg s.c. (4-weekly) nasopharyngitis 21.8% headache 7.8% diarrhoea 4.4% NCT02474069 · Phase 3 · registry result, not featured evidence nasopharyngitis 28.6% (placebo 28.9%) headache 7.1% (placebo 2.6%) hypertension 4.8% (placebo 5.3%) NCT02362789 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 29.1% oropharyngeal pain 16.2% headache 15.6% NCT01961609 · Phase 3 · registry result, not featured evidence 150 mg headache 23.5% nasopharyngitis 23.5% psoriasis 13% NCT01961609 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 28.7% headache 14.9% upper respiratory tract infection 12.5% NCT02074982 · Phase 3 · registry result, not featured evidence nasopharyngitis 51.4% headache 14.3% diarrhoea 6.7% NCT02474082 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 52 weeks versus 24 weeks.
- eAssessment timepoints differ: 32 weeks versus 52 weeks.
- fTrial phases differ: Phase 4 versus Phase 3.
- gAssessment timepoints differ: 4 weeks versus 192 weeks.
- hTrial phases differ: Phase 3 versus Phase 2.
- iAssessment timepoints differ: 4 weeks versus 52 weeks.
- jPopulation context differs: registered conditions differ.
- kTrial phases differ: Phase 3 versus Phase 4.
- lAssessment timepoints differ: 32 weeks versus 24 weeks.
- mAssessment timepoints differ: 132 weeks versus 52 weeks.
- nPopulation comparability has not been reviewed for 76 of these studies.
- oPopulation comparability has not been reviewed for 78 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ixekizumab
show 10 more results
show 1 more result
show 1 more result
show 4 more results
show 1 more result
show 13 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 101 further endpoints in the CSV export.
secukinumab
show 1 more result
show 1 more result
show 3 more results
show 22 more results
show 51 more results
show 1 more result
show 9 more results
show 17 more results
show 17 more results
show 3 more results
show 1 more result
show 1 more result
+ 135 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ixekizumab's landscape · secukinumab's landscape